VICKI DEWEESE: Open Payments
NPI 1164411559 · DALTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,922 in 96 payments from 14 companies in 2025. Trend: 2023 $1,817 · 2024 $2,199 · 2025 $1,922
Food & beverage: $1,922
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $386 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $362 |
| Supernus Pharmaceuticals, Inc. | 11 | $241 |
| Otsuka America Pharmaceutical, Inc. | 12 | $199 |
| ABBVIE INC. | 14 | $186 |
| Teva Pharmaceuticals USA, Inc. | 5 | $129 |
| Alkermes, Inc. | 4 | $93 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Lundbeck LLC | 2 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
Products named: INGREZZA, CAPLYTA, Qelbree, VRAYLAR, REXULTI, ABILIFY ASIMTUFII, Auvelity, ARISTADA.
Industry payments across GA — which companies pay providers there.
